.jpg)
1 hour ago
3
Shares of Wockhardt tumbled as much as 7% to their day’s low of Rs 2,005 on the BSE on Tuesday, halting an impressive 36% rally in just five sessions. The drop comes as investors took profits off the table following the surge.
In the previous session, shares rallied 6% after the company announced that the U.S. Food and Drug Administration (FDA) has approved ZAYNICH (cefepime and zidebactam), a novel intravenous antibiotic for treating adults with complicated urinary tract infections (UTI), including pyelonephritis, caused by susceptible Gram-negative pathogens.
According to the company, ZAYNICH combines the fourth-generation cephalosporin cefepime with zidebactam and is designed to target multiple penicillin-binding proteins simultaneously. The antibiotic had earlier received Qualified Infectious Disease Product (QIDP) and Fast Track designations from the FDA.
The approval comes at a time when antimicrobial resistance remains a major healthcare challenge. Wockhardt cited data indicating that more than 2.8 million antimicrobial-resistant infections occur annually in the United States, resulting in over 35,000 deaths each year.
Wockhardt Q4 snapshot
The company reported a sharp turnaround in its March quarter performance and improved full-year earnings. The pharmaceutical company reported a net profit of Rs 164 crore in Q4FY26, compared with a loss of Rs 45 crore in the same period last year. Revenue rose 30% year-on-year to Rs 965 crore, up from Rs 743 crore in Q4FY25.
EBITDA also recorded strong growth of 147%, rising to Rs 196 crore from Rs 79 crore a year earlier.
For FY26, Wockhardt posted revenue of Rs 3,373 crore, up 11% from Rs 3,033 crore in the previous year. EBITDA increased 51% to Rs 630 crore from Rs 418 crore, reflecting improved operating performance across segments.
Biotech operations were a key growth driver, contributing Rs 252 crore in the quarter, a 126% increase over Q4FY25. On a full-year basis, biotech revenue rose 27% to Rs 697 crore, supported by strong momentum in emerging markets, where growth exceeded 34%. Expansion was aided by new partnerships and deals across Thailand, Egypt, Algeria, and Latin America, while domestic biotech operations continued to grow at a double-digit pace.
The company reported continued expansion in its product pipeline, with 15 filings, 13 approvals, and 23 launches in international markets. In biosimilars, it recorded 11 filings and 16 approvals, while the NCE segment saw 4 filings and 1 approval. It also secured approvals for EMROK O and EMROK injection in Uganda.
Wockhardt share price performance
The shares of the company have risen 41% in the last 1 year and about 233% in the last five years.
(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)
English (US)